title: Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy.
abstract: BACKGROUND
  Reports are mixed as to whether highly active antiretroviral therapy (HAART) increases liver transaminase levels or hepatitis C virus (HCV) titers in HIV/HCV-coinfected individuals. It is hypothesized that increases in HCV RNA titers may result from changes in endogenous interferon-alpha (IFN-alpha) production.
  
  
  METHODS
  HIV/HCV-coinfected patients receiving HAART were tested at baseline, 1, 2, 3, 6, and 9 months for liver transaminase levels, HIV and HCV viral loads, and IFN-alpha. Linear regression analysis was used to determine the effect of HAART on liver transaminase levels, HCV viral load, and IFN-alpha.
  
  
  RESULTS
  Initiating HAART did not increase liver transaminase levels in majority of cases. In patients (n = 30) with baseline HIV titer >10,000 copies/mL, HCV titers increased 0.69 log10 and IFN-alpha decreased -0.96 log10 during HAART, in association with a > or =0.5 log10 decrease in HIV titer. As HIV titers reached their nadir approximately 4 months after initiation of HAART, HCV titers remained 0.54 log10 and IFN-alpha -0.71 log10 above and below baseline levels, respectively. HCV titers and IFN-alpha levels did not change from baseline in patients with baseline HIV titer < or =10,000 copies/mL.
  
  
  CONCLUSIONS
  Coinfected patients did not have evidence of hepatoxicity HAART. In patients with baseline HIV titer >10,000 copies/mL, suppression of HIV replication by HAART was associated with an increase in HCV titer and a decrease in endogenous IFN-alpha levels.
authors.affiliation: Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. wab4@cdc.gov
authors.forename: William A
authors.initials: WA
authors.lastname: Bower
authors.forename: David H
authors.initials: DH
authors.lastname: Culver
authors.forename: Delivette
authors.initials: D
authors.lastname: Castor
authors.forename: Yingfeng
authors.initials: Y
authors.lastname: Wu
authors.forename: V Nicole
authors.initials: VN
authors.lastname: James
authors.forename: Haoqiang
authors.initials: H
authors.lastname: Zheng
authors.forename: Scott
authors.initials: S
authors.lastname: Hammer
authors.forename: Wendi L
authors.initials: WL
authors.lastname: Kuhnert
authors.forename: Ian T
authors.initials: IT
authors.lastname: Williams
authors.forename: Beth P
authors.initials: BP
authors.lastname: Bell
authors.forename: David
authors.initials: D
authors.lastname: Vlahov
authors.forename: Charlene S
authors.initials: CS
authors.lastname: Dezzutti
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification*; D006526:Hepatitis C / Q000097:blood / Q000150:complications / Q000821:virology*; D006801:Humans; D016898:Interferon-alpha / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load
chemical_list: D016898:Interferon-alpha; D012367:RNA, Viral